Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
2 hedge funds and large institutions have $270K invested in Karuna Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 325 closing their positions.
99% less funds holding
Funds holding: 328 → 2 (-326)
100% less funds holding in top 10
Funds holding in top 10: 26 → 0 (-26)
100% less capital invested
Capital invested by funds: $12B → $270K (-$12B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 325
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$1.34B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.02B |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$907M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$858M |
| 5 |
BlackRock
New York
|
-$638M |
KRTX Hedge Fund Activity: Q1 2024 in Review
2 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q1 2024, worth a combined $270K — down 100% from $12B a quarter earlier.
Sellers outnumbered buyers: 325 funds closed out of KRTX and 0 opened new positions — a net loss of 325 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Capital International Investors, exiting entirely with an estimated $1.34B sold.
- 2 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q1 2024, down from 328 in Q4 2023.
- Funds reported $270K of Karuna Therapeutics, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q1 2024 and 325 closed out, a net change of -325 holders.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q1 2024 was Capital International Investors, an estimated $1.34B sold.
Based on aggregated 13F filings for Q1 2024.